Purpose: Detection of cortical abnormalities in relapsing-remitting multiple sclerosis (RRMS) remains elusive. Structural magnetic resonance imaging (MRI) measures of cortical integrity are limited, although functional techniques such as pseudo-continuous arterial spin labeling (pCASL) show promise as a surrogate marker of disease severity. We sought to determine the utility of pCASL to assess cortical cerebral blood flow (CBF) in RRMS patients with (RRMS-I) and without (RRMS-NI) cognitive impairment. Methods: A total of 19 age-matched healthy controls and 39 RRMS patients were prospectively recruited. Cognition was assessed using the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery. Cortical CBF was compared between groups using a mass univariate voxel-based morphometric analysis accounting for demographic and structural variable covariates. Results: Cognitive impairment was present in 51.3% of patients. Significant CBF reduction was present in the RRMS-I compared to other groups in left frontal and right superior frontal cortex. Compared to healthy controls, RRMS-I displayed reduced CBF in the frontal, limbic, parietal and temporal cortex, and putamen/thalamus. RRMS-I demonstrated reduced left superior frontal lobe cortical CBF compared to RRMS-NI. No significant cortical CBF differences were present between healthy controls and RRMS-NI. Conclusion: Significant cortical CBF reduction occurs in RRMS-I compared to healthy controls and RRMS-NI in anatomically significant regions after controlling for structural and demographic differences.
Introduction
Multiple sclerosis (MS) is the most frequent cause of non-traumatic neurological disability in young and middle-age adults and the most common inflammatory demyelinating disease of the central nervous system. In total, 40%-65% of MS patients experience cognitive dysfunction. 1 While MS is traditionally viewed as a predominantly white matter (WM) disease, only modest associations between T2-weighted hyperintense WM lesions, T1 holes, and cognitive test performance have been reported. 2 An interdependent relationship is reported between normal appearing white matter (NAWM) axonal and gray matter (GM) damage in primary progressive MS patients, 3 yet a more recent study demonstrated cortical abnormality in the absence of WM disease. 4 Cortical involvement is reported in 59%-93% of MS cases significantly contributing to the progression of both physical and cognitive disability. 5, 6 Cortical volume loss also demonstrates a stronger association for cognitive dysfunction than for whole brain atrophy. 7 Arterial spin labeling (ASL) is a non-invasive quantitative perfusion imaging technique utilizing inflowing cerebral blood as an endogenous tracer measuring cerebral blood flow (CBF). 8 Pseudocontinuous arterial spin labeling (pCASL) combines the advantages of both pulsed and continuous ASL yielding higher signal-to-noise ratio (SNR), higher tagging efficiency, and reduced transit time sensitivity when compared to pulsed ASL. 9 pCASL is a robust clinical method to measure in vivo perfusion changes, used to detect perfusion abnormalities in patients with neurodegenerative disorders and MS. 10 Recently, Debernard et al. 10 showed differences in cortical CBF between healthy controls and early relapsing-remitting multiple sclerosis (RRMS) in the absence of cortical volume differences. No significant cortical CBF differences were present between healthy controls and early RRMS for several cognitive tests although a trend to impairment in the visual memory domain (Brief Visual Memory Test) was present in the early RRMS group. A strong positive association was seen between cortical CBF and visual memory. Similarly, Aviv et al. demonstrated significant cortical cerebral blood volume (CBV) differences between cognitively unimpaired and impaired secondary progressive multiple sclerosis (SPMS) patients after controlling for confounding factors of atrophy and WM disease. 11 Cortical perfusion differences in both studies suggest a potential utility of CBF and CBV as surrogate markers of cortical disease activity and cognition. We sought to validate and extend upon these two prior studies and hypothesized that significant pCASL-derived cortical CBF differences exist between RRMS patients with and without cognitive impairment and healthy controls after controlling for clinical and structural confounders. 10
Methods

Patients
Approval for this study was obtained from research ethics boards of Sunnybrook and St. Michael's hospitals. Thirty-nine RRMS patients were prospectively recruited during a 1-year period from two tertiary referral MS clinics. Initially, 20 patients demonstrating impairment with a Montreal Cognitive Assessment (MoCA) screen were selected followed by 19 age-and gender-matched unimpaired RRMS patients. RRMS diagnosis was determined using the 2010 revised McDonald 12 criteria by a senior neurologist with specialist practice in MS (20 years of experience). Exclusion criteria were as follows: history of drug/ alcohol abuse, use of steroids within the past 3 months, premorbid (i.e. pre-MS) psychiatric history, head injury with loss of consciousness, concurrent medical diseases (e.g. cerebrovascular disease), and contraindication to magnetic resonance imaging (MRI). Clinical data included age, gender, education level, and disease duration. MRI acquisition, neurocognitive examination, and expanded disability status scale (EDSS) assessment 13 were completed on the same day. Nineteen age-matched healthy participants were also recruited as controls for the study.
Cognitive testing
The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) was administered under the supervision of a senior neuropsychiatrist. 14 This standard MS cognitive battery is a comprehensive assessment tool consisting of seven neuropsychological tests as follows: Paced Auditory Serial Addition Test (PASAT) to assess working memory, Symbol Digit Modalities Test (SDMT) to assess processing speed, California Verbal Learning Test (CVLT)-Second Edition to assess verbal memory, revised Brief Visuospatial Memory Test (BVMT) to assess visuospatial memory, Delis-Kaplan Executive Function System (D-KEFS) to assess executive function, Controlled Word Association Test (COWAT) to assess verbal fluency, and Judgment of Line Orientation (JLO) to assess visuospatial perception. Raw test scores were converted to Z scores, and impairment on an individual test was defined as scoring more than 1.5 standard deviations below normative data. 15 Z scores are derived from populationrepresentative or normalized data that correct for educational level for three key neurocognitive constituents of the MACFIMS battery, namely, PASAT, SDMT, and COWAT. Patients with two or more test impairments were designated as having cognitive impairment. 15 Hospital Anxiety and Depression Scores (HADS-A and HADS-D) were also obtained due to the association between depression/ anxiety and cognitive impairment in MS patients. 16, 17 MRI acquisition MRI scanning was performed on a Philips 3T scanner (Philips Healthcare, Andover, MA, USA) with an eightchannel phased array coil. The following sequences were acquired: T1 3D (repetition time/echo time (TR/TE): 9.5 ms/2.3 ms, resolution: 0.63 × 0.63 × 1.2 mm 3 ), PD/T2 (TR/TE: 2500 ms/10.7 ms, resolution: 0.63 × 0.63 × 1.2 mm 3 ), phase-sensitive inversion recovery (PSIR; TR/TE: 3374 ms/15 ms, field of view (FOV): 23 cm, matrix: 400 × 255, resolution: 0.43 × 0.43 × 3mm 3 ), pCASL acquisition for CBF signal (TR/TE: 4000/ 9.7 ms, 64 × 64 × 18 matrix, resolution: 3 × 3 × 5 mm 3 , label offset: 80 mm, post label delay (PLD): 1600 ms, label duration: 1650 ms, and scan duration of 248 seconds (30 Tag control pair)), and reference ASL acquisition for absolute quantification of CBF (TR/ TE: 10,000/9.7 ms, 64 × 64 × 18 matrix, resolution: 3 × 3 × 5 mm 3 , and scan duration of 40 seconds).
Image processing
We used an image processing pipeline developed by Shirzadi et al. 18 to derive CBF maps. Briefly, GM voxels were automatically segmented on the T1-weighted image (FMRIB's Automated Segmentation Tool (FAST)). 19 T1-weighted images with the overlaid tissue masks were then coregistered to the ASL coordinate space. GM detectability metric was iteratively calculated using an aligning/sorting/ discarding/refining pipeline. 18 The point of maximum GM detectability was then identified and only intermediate perfusion images contributing to this peak level were used in the calculation of the optimized CBF estimate. 18 The reference pCASL scans were transformed to MNI 152 space (Montreal Neurological Institute, McGill University) using the normalize function in Statistical Parametric Mapping 8 (SPM 8; Wellcome Department of Imaging Neuroscience, London, UK). The scans in MNI 152 space were then averaged to form a study-specific MNI template. Individual CBF maps were coregistered to the study-specific MNI template using a linear registration (FMRIB's Linear Image Registration Tool (FSL-FLIRT)) followed by non-linear intensity modulation and multi-resolution FMRIB's non-linear image registration tool (FSL-FNIRT) with four subsampling levels. The CBF maps were smoothed at each respective resolution level using full-width half-max Gaussian kernels of 6, 4, 2, and 2 mm. The perfusion measures at each voxel were then statistically analyzed using the analyses described below.
Statistical analysis
Clinical and demographic measures. To compare each demographic, clinical, and volume data among three groups, univariate general linear regression was performed on all continuous outcomes such as age, educational years, and all brain volume data. For categorical variables such as gender, logistic regression was conducted. Statistical Analysis Software (SAS version 9.4 for windows) was used for analysis.
Voxel-based analysis
Mass univariate methodology of SPM8 was used to perform a voxel-by-voxel two-sample t test between the study groups to assess the regional GM CBF differences measured in mL/100 g/min (i.e. the test comparisons include (1) healthy controls versus RRMS-I, (2) healthy controls versus RRMS-NI, and (3) RRMS-NI vs RRMS-I). 20 Significance was defined as a voxel-wise p threshold (Bonferroni-adjusted p < 0.01) and an extent threshold of 20 contiguous voxels. The clinical and demographics measures that were significantly different (p < 0.05) between the test groups were considered as confounders to be added in the respective mass univariate analysis. Xjview software 8.12 (http://www.alivelearn.net/ xjview) was used to extract the brain regions where focal differences were found. Similar voxel-wise analyses were performed to assess voxel-wise structural differences between study groups based on T1 structural images segmented using both unified space segmentation and DARTEL functions in SPM8. This was achieved by registering each participant's native space segmentation to a groupspecific template created using the DARTEL space segmentations. The registered segmentations were then affine-transformed into MNI space and smoothed with an 8-mm full-width half-maximum (FWHM) isotropic Gaussian kernel.
Results
Clinical and demographic characteristics
Of the 39 RRMS prospectively recruited patients, 20 (51.3%) were cognitively impaired. Compared to healthy controls, RRMS-NI (p = 0.0117) and RRMS-I (p = 0.0004) demonstrated higher HADS-A scores. A higher HADS-D scores were present in RRMS-I patients (p < 0.0001) compared to both RRMS-NI and healthy controls. RRMS-I patients demonstrated reduced years of education (p = 0.0038), lower normalized global brain parenchymal fraction (BPF; p = 0.0149), lower global WM volume (p = 0.0079), and increased global cerebrospinal fluid (CSF) volume (p = 0.0065) compared to healthy controls. No significant difference in normalized global cortical volume was found in either of the RRMS subgroups compared to healthy controls (Table 1) .
Voxel-based analysis
Voxel-based analysis demonstrated reduced cortical CBF in RRMS-I group compared to RRMS-NI and healthy controls in the left frontal (pre-and postcentral gyrus: Brodmann area (BA) 6 including supplementary motor area and BA4, respectively) and right superior frontal lobes (BA 10 and BA 6 including supplementary motor area). Compared to healthy controls, RRMS-I also displayed reduced GM CBF in the left middle frontal (BA 9 and 10), bilateral inferior frontal (BA 11, 46, and 47), bilateral limbic (cingulate gyrus, BA 32), bilateral parietal (postcentral gyrus, supramarginal gyrus, and BA 2, 3, and 40), bilateral temporal (right middle temporal gyrus, and BA 20 and 21) lobes, right putamen, and left thalamus/pulvinar ( Table 2) . Compared with RRMS-NI, RRMS-I demonstrated reduced cortical GM CBF in the left superior frontal (supplementary motor area, BA 6) lobe (Table 3; Figure 1 ). No cortical GM CBF differences were observed between healthy controls and RRMS-NI. No regional voxel-wise structural differences were present between RRMS subgroups to account for perfusion abnormality.
Discussion
After controlling for structural and/or demographic group confounders, we observed significant cortical controls. Reduced left superior frontal gyrus cortical CBF was present compared to RRMS-NI.
Reduced CBF in the temporal, frontal, and postcentral gyri as well as deep GM (left thalamus and right putamen) were similarly reported by Debernard et al. 10 In contrast, we did not find any CBF differences in the lingual gyrus, intracalcarine, insular and operculum cortex, temporal fusiform cortex, superior parietal lobule, precuneus cortex, frontal orbital cortex, right thalamus, left hippocampus, or right caudate. Furthermore, no cortical CBF differences were observed in our study between healthy controls and RRMS-NI. These discrepancies could be explained by important differences in the patient populations in each study. Unlike Debernard who reported borderline significant BVMT reduction in their "early" RRMS-NI cohort compared to healthy controls, we observed no significant difference in cognitive test scores between RRMS-NI and healthy control groups. This suggests a higher disease burden in their unimpaired RRMS patients; an assumption supported by a higher EDSS upper range of 4.5 compared to 3.5 in our study despite similar median EDSS values of 1.5.
Significant CBF reduction in BA 6 was seen in RRMS-I patients compared to both healthy controls and RRMS-NI. This region is functionally important for numerical and verbal mental-operation tasks, 21 as well as encoding and recognition within the context of working memory and long-term memory tasks. 22 Abnormalities in these regions are consistent with the finding of significant impairments related to working (PASAT and SDMT) and long-term memory (BVMT and CVLT) observed in the RRMS-I group compared to both RRMS-NI and healthy controls ( Table 1 ).
The parietal lobe (especially superior parietal lobe) plays an important role in spatial cognition and constitutes a part of the dorsal visual processing system which is responsible for encoding of the spatial location of stimuli. 23 Sack et al. 23 utilized functional magnetic resonance imaging (fMRI) to demonstrate bilateral parietal activity during the execution of spatial cognition tasks and observed significant spatial cognition deficits after inducing right parietal neural activity disruptions with transmagnetic stimulation.
In another fMRI study, participants performed auditory and visual tasks alone and simultaneously with working memory tasks. Analysis revealed that while the majority of activation identified during individual tasks was also activated in the dual task condition, several neural substrates such as left middle frontal gyrus, left superior parietal lobule, posterior region of right inferior temporal gyrus, and bilateral parahippocampal gyri were selectively activated during the dual tasks. 24 The authors concluded that new neural networks are activated to assist with the greater load placed on working memory. 24 The distribution of activations associated with working memory correspond with the CBF reductions, which we demonstrated in RRMS-I patients of the present cohort.
GM CBF reduction in MS could be explained through primary and secondary pathogenic mechanisms, which cumulatively cause GM demyelination and axonal degeneration. 25 Magliozzi et al. 26 showed a spatial relation between ectopic meningeal B-cell follicles and a superficial to deep gradient of cortical pathology suggesting that cortical subpial demyelination results from primary meningeal, rather than cortical lesion inflammation possibly mediated through a soluble cytotoxic/myelinotoxic factor. Secondary GM neuroaxonal degeneration occurs in association with amyloid precursor protein positive active WM lesions, with abnormal sodium channel distribution resulting in higher ATP production causing "virtual hypoxia." 27, 28 Other secondary mechanisms of GM demyelination include variable firing patterns in different repertoires of sodium channels, glutamate imbalance leading to excitotoxicity and axonal damage, and selective response to acetylcholinesterase inhibitor invastigmine. [29] [30] [31] We and others have previously demonstrated the presence of perfusion differences in the absence of structural abnormality in RRMS patients without and with cognitive impairment and in healthy controls compared to early RRMS, respectively. 10, 32 Cortical perfusion reduction was also independent of WM volume suggesting a primary vascular or mitochondrial disturbance as the most likely etiology.
A limitation of pCASL is its intrinsically low SNR and unexpected variations of control and tag images resulting from head motion, physiological noise, and hardware instabilities. 33 To circumvent these issues, we utilized a pipeline to discard ASL pairs that do not pass "detectability criteria." This approach is shown to improve detection of CBF in GM. 18 The effect of disease-modifying drugs on perfusion is unknown and therefore we initially tested for differences of drug class usage between the RRMS subgroups. In the absence of differences, a confounding effect was considered unlikely, and this variable was not included in our voxel-based morphometry (VBM) analysis. Depression is shown to have an effect on cognition and cerebral perfusion although is seldom considered a confounding covariate in the literature. Hypoperfusion was observed in right inferior prefrontal cortex and anterior cingulate cortices in middle-age adults with major depressive disorder and in frontal, limbic, paralimbic, and cingulate in adolescent population suffering from depression. 16, 34, 35 Given the demonstrated differences between groups for HADS performance, we accounted for its effect on perfusion and cognition by including the HADS-D scores as covariates in the voxel-based analysis. Finally, despite a small group sample size, we showed significant group differences; however, these results should be validated in larger series.
In conclusion, significant GM CBF reduction in anatomically significant regions associated with cognition after controlling for structural and demographic differences suggests that pCASL-derived CBF may provide surrogate measures of RRMS disease severity; however, this requires validation in larger studies.
